Table 2.

GLP-1R agonists in clinical trials for PD. A variety of FDA-approved and newly developed (*) GLP-1R agonists either have completed trials or are currently in progress. SC = subcutaneous; # clinical trials can be located at www.clinicaltrials.gov.

Company	Drug name		PD clinical trial information
AstraZeneca	Exenatide	Byetta®	Phase 2 clinical trial completed (#NCT01174810) (See Aviles-Olmos et al., 2013)
		Bydureon®	Phase 2 clinical trial completed (#NCT01971242) (See Athauda et al., 2017)
			Phase 1 clinical trial recruiting (#NCT0346687)
			Phase 2 clinical trial recruiting (#NCT04305002)
			Phase 3 clinical trial not yet recruiting (#NCT04232969)
Peptron Inc.	Exenatide SR	*PT-302	Phase I clinical trial completed (#NCT00964262)
			Phase 2 clinical trial recruiting (#NCT04269642)
Neuraly Inc.	Exenatide	*NLY01	Phase 1 clinical trial completed (#NCT03672604) (See Yun et al., 2018)
			Phase 2 clinical trial recruiting (#NCT04154072)
Novo Nordisk	Liraglutide	Victoza®	Phase 2 clinical trial recruiting (#NCT02953665)
	Semiglutide	Ozempic®	Phase 2 clinical trial not yet recruiting (#NCT03659682)
Sanofi-Aventis	Lixesentatide	Adlyxin®	Phase 2 clinical trial recruiting (#NCT03439943)